HEPA
Hepion Pharmaceuticals Inc
Halal Rating :
Last Price
$0.47
Last updated:
Market Cap
-
7D Change
-5.52%
1 Year Change
-77.71%
Company Overview
Industries
Exchange
Next Earnings Date
Hepion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of liver diseases. Their lead drug candidate, rencofilstat (CRV431), is being developed for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The company is currently in clinical trials and does not yet generate revenue from product sales.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
Company Impact
Help us evaluate Hepion Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.